SQZ Biotechnologies Co financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
200 Arsenal Yards Blvd., Ste. 210, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 8, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 286 % -30%
Debt-to-equity 108 % +10.3%
Return On Equity -232 % -187%
Return On Assets -112 % -173%
Operating Margin -376 % -48%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.5M shares +0.14%
Common Stock, Shares, Outstanding 29.5M shares +0.48%
Entity Public Float 80.3M USD -77%
Common Stock, Value, Issued 29K USD 0%
Weighted Average Number of Shares Outstanding, Basic 29.5M shares +0.71%
Weighted Average Number of Shares Outstanding, Diluted 29.5M shares +0.71%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 178K USD -94.5%
Revenue from Contract with Customer, Excluding Assessed Tax 178K USD -94.1%
Research and Development Expense 51.8M USD -28.7%
Operating Income (Loss) -73.2M USD +6.74%
Nonoperating Income (Expense) 1.55M USD +108%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -71.6M USD +7.84%
Earnings Per Share, Basic -2.43 USD/shares -3.9%
Earnings Per Share, Diluted -2.43 USD/shares -3.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.2M USD -87.9%
Assets, Current 12.1M USD -86.2%
Property, Plant and Equipment, Net 978K USD -61.2%
Operating Lease, Right-of-Use Asset 14.4M USD -76.9%
Assets 29.8M USD -80.8%
Accounts Payable, Current 1.91M USD -42.2%
Accrued Liabilities, Current 4.35M USD -44.4%
Liabilities, Current 8.83M USD -65%
Operating Lease, Liability, Noncurrent 19.1M USD -63.2%
Liabilities 27.9M USD -67.7%
Retained Earnings (Accumulated Deficit) -333M USD -27.4%
Stockholders' Equity Attributable to Parent 1.88M USD -97.3%
Liabilities and Equity 29.8M USD -80.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.8M USD -16.3%
Net Cash Provided by (Used in) Investing Activities -65K USD +66.5%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 29.5M shares +0.48%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12.5M USD -85.6%
Deferred Tax Assets, Valuation Allowance 84.2M USD +34.4%
Deferred Tax Assets, Gross 91.5M USD +11.6%
Operating Lease, Liability 27.5M USD -60.6%
Payments to Acquire Property, Plant, and Equipment 65K USD -71.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -71.6M USD +7.84%
Lessee, Operating Lease, Liability, to be Paid 36M USD -59%
Property, Plant and Equipment, Gross 7.37M USD -3.42%
Operating Lease, Liability, Current 2.4M USD -77.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.3M USD -71.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 8.66M USD -41.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +13.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.56M USD -53.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.43M USD -70.5%
Deferred Tax Assets, Operating Loss Carryforwards 50.2M USD +16.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.56M USD -69.9%
Operating Lease, Payments 3.66M USD +16.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.14M USD -1.3%
Deferred Tax Assets, Net of Valuation Allowance 7.29M USD -62.3%
Share-based Payment Arrangement, Expense 4.6M USD -48.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%